Reports
Sale
Global Huntington’s Disease Treatment Market Share, Size, Growth, Trends, Insights, Analysis, Forecast: By Treatment Method: Symptomatic Treatment, Disease-modifying Therapies, Palliative Care Treatment, Others; By Diagnosis Method; By Drug Class; By Treatment Channel; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Global Huntington’s Disease Treatment Market Outlook
The global Huntington’s disease treatment market was estimated to be worth USD 446.08 million in 2023 and is likely to grow at a rate of 16% during the forecast period of 2024-2032. Driven by the growing demand and increasing R&D activities, the market is likely to attain a value of about USD 1,696.42 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Huntington’s Disease Treatment Market: Introduction
The global Huntington's disease treatment market report by Expert Market Research provides an in-depth analysis of the market and its segments. Huntington's disease is a rare, inherited neurodegenerative disorder that affects a small percentage of the global population. The lack of effective treatments for Huntington's disease has been a major challenge for healthcare providers and researchers worldwide. The report covers the market for Huntington's disease treatment and provides a detailed analysis of the market size, growth, and trends.
The Huntington's disease treatment market is expected to witness significant advancements in the coming years. The development of novel therapies, such as gene therapy and RNA interference, and the increasing focus on personalized medicine are likely to drive the growth of the market. Additionally, the expansion of healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to create lucrative opportunities for the market players.
Moreover, the growing adoption of telemedicine and digital health technologies may provide new avenues for the management and treatment of Huntington's disease, potentially improving patient outcomes and reducing healthcare costs. As a result, the global Huntington's disease treatment market is expected to continue its growth trajectory throughout the forecast period, offering numerous opportunities for key players and investors in the industry.
Huntington’s Disease Epidemiology
Huntington's disease is a rare inherited disorder that affects the brain and nervous system. The disease is caused by a genetic mutation that leads to the progressive breakdown of nerve cells in the brain. Huntington's disease affects people of all races and ethnicities, with an estimated prevalence of 5-10 cases per 100,000 people worldwide.
The onset of Huntington's disease typically occurs in midlife, with symptoms appearing between the ages of 30 and 50 years. The disease is characterized by a progressive loss of motor control, cognitive decline, and psychiatric symptoms. Currently, there is no cure for Huntington's disease, and the available treatments only provide symptomatic relief.
The prevalence of Huntington's disease varies across different regions of the world. The disease is more common in certain populations, such as those of European ancestry, and less common in others, such as those of Asian and African descent. In North America and Europe, the prevalence of Huntington's disease is estimated to be between 5 and 10 cases per 100,000 people, while in Asia and Africa, the prevalence is lower, at around 1 case per 100,000 people.
The incidence of Huntington's disease is also influenced by gender, with men and women being affected at similar rates. However, the age of onset may be slightly earlier in men than in women.
Huntington’s Disease Treatment Market Segmentations
The market can be categorised into treatment method, diagnosis method, drug class, treatment channel, and major region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Treatment Method
- Symptomatic Treatment
- Disease-modifying Therapies
- Palliative Care Treatment
- Others
Market Breakup by Diagnosis Method
- Neurological Exams and Neuropsychological Tests
- Psychiatric Evaluation
- Brain-Imaging and Function Tests
- Genetic Counselling
- Predictive Genetic Tests
- Others
Market Breakup by Drug Class
- Mood Stabilizers
- Antipsychotic Drugs
- Antidepressants
- Others
Market Breakup by Treatment Channel
- Public
- Private
Huntington’s Disease Treatment Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Huntington’s Disease Treatment Market Scenario
North America dominates the Huntington's disease treatment market, followed by Europe and the Asia Pacific. The high prevalence of Huntington's disease in North America and Europe, coupled with the favorable reimbursement policies, is driving the growth of the market in these regions. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about Huntington's disease and the rising healthcare expenditure in the region.
The market is highly fragmented, with numerous small and mid-sized companies operating in the market. The lack of effective treatments for Huntington's disease has led to the emergence of a large number of companies focusing on the development of innovative therapies for this disorder.
Key Players in the Global Huntington’s Disease Treatment Market
The report gives an in-depth analysis of the key players involved in the Huntington’s Disease Treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- H. Lundbeck A/S
- Teva Pharmaceutical Industries Ltd.
- Bausch Health Companies Inc.
- Hetero Drugs Limited
- Lupin Limited
- Hikma Pharmaceuticals plc
- Dr Reddy’s Laboratories Ltd
- Sun Pharmaceutical Industries Limited
- SOM Biotech
- Annexon, Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Method |
|
| Breakup by Diagnosis Method |
|
| Breakup by Drug Class |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Huntington’s Disease Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Huntington’s Disease Treatment Market
8.1 Global Huntington’s Disease Treatment Market Overview
8.2 Global Huntington’s Disease Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Huntington’s Disease Treatment Market Historical Value (2017-2023)
8.2.1.2 Global Huntington’s Disease Treatment Market Forecast Value (2024-2032)
8.2.2 Global Huntington’s Disease Treatment Market by Treatment Method
8.2.2.1 Market Overview
8.2.2.1.1 Symptomatic Treatment
8.2.2.1.2 Disease-modifying Therapies
8.2.2.1.3 Palliative Care Treatment
8.2.2.1.4 Others
8.2.3 Global Huntington’s Disease Treatment Market by Diagnosis Method
8.2.3.1 Market Overview
8.2.3.1.1 Neurological and Neuropsychological Tests
8.2.3.1.2 Psychiatric Evaluation
8.2.3.1.3 Brain-Imaging and Function Tests
8.2.3.1.4 Genetic Counselling
8.2.3.1.5 Predictive Genetic Tests
8.2.3.1.6 Others
8.2.4 Global Huntington’s Disease Treatment Market by Drug Class
8.2.4.1 Market Overview
8.2.4.1.1 Mood Stabilizers
8.2.4.1.2 Antipsychotic Drugs
8.2.4.1.3 Antidepressants
8.2.4.1.4 Others
8.2.5 Global Huntington’s Disease Treatment Market by Treatment Channel
8.2.5.1 Market Overview
8.2.5.1.1 Public
8.2.5.1.2 Private
8.2.6 Global Huntington’s Disease Treatment Market by Region
8.2.6.1 Market Overview
8.2.6.1.1 North America
8.2.6.1.2 Europe
8.2.6.1.3 Asia Pacific
8.2.6.1.4 Middle East and Africa
8.2.6.1.5 Latin America
9 North America Huntington’s Disease Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 Canada
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
10 Europe Huntington’s Disease Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Germany
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 France
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Italy
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
10.6 Others
11 Asia Pacific Huntington’s Disease Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 Japan
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 India
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 ASEAN
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Australia
11.6.1 Historical Trend (2017-2023)
11.6.2 Forecast Trend (2024-2032)
11.7 Others
12 Latin America Huntington’s Disease Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Argentina
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Mexico
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
12.5 Others
13 Middle East and Africa Huntington’s Disease Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2017-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 United Arab Emirates
13.3.1 Historical Trend (2017-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 Nigeria
13.4.1 Historical Trend (2017-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 South Africa
13.5.1 Historical Trend (2017-2023)
13.5.2 Forecast Trend (2024-2032)
13.6 Others
14 Global Huntington’s Disease Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 H. Lundbeck A/S
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Teva Pharmaceutical Industries Ltd.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Bausch Health Companies Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Hetero Drugs Limited
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Lupin Limited
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Hikma Pharmaceuticals plc
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Dr. Reddy’s Laboratories Ltd
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Sun Pharmaceutical Industries Limited
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 SOM Biotech
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Annexon, Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
16 Global Huntington’s Disease Treatment Market- Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 446.08 million in 2023.
The market is likely to grow at a rate of 16% during the forecast period of 2024-2032 to attain a value of USD 1,696.42 million by 2032.
The market is primarily driven by the rising cases of Huntington’s disease, increasing research and developmental activities and novel product launches and approvals.
Based on the drug class, the market is categorised into mood stabilizers, antipsychotic drugs, antidepressants, and others.
Based on the diagnosis method, the market is segmented into neurological exams and neuropsychological tests, psychiatric evaluation, brain-imaging and function tests, genetic counselling, predictive genetic tests, and others.
Based on the treatment method, the market is bifurcated into symptomatic treatment, disease-modifying therapies, and palliative care treatment, among others.
Based on the treatment channel, the market is divided into public and private.
The different regions in the market are North America, Europe, Asia Pacific, Latin America the Middle East and Africa. North America is anticipated to hold a largest share of the market during the forecast period.
The key companies involved in the market are H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Hetero Drugs Limited, Lupin Limited, Hikma Pharmaceuticals plc, Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Limited, SOM Biotech, and Annexon, Inc., among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER